Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05429632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05429632 · ClinicalTrials.gov record · last posted 2026-07-17

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Study acronym: MO-TRANS
StatusRecruiting
PhasePhase 3
Started2022-06-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a multi-center, randomized, double-blinded, placebo controlled trial.

Amendment record 68 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 68 times since 2022-06-17; most recent amendment 2026-07-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-05-13
Status change Active, Not Recruiting→Recruitingv57
2024-11-21
Status change Recruiting→Active, Not Recruitingv53
2022-11-08
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05429632
Lead Sponsor Priothera SAS
Conditions Adult Acute Myeloid Leukemia
Enrollment 366 participants
Start Date 2022-06-16
Primary Completion 2027-05 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-17